May 29, 2026
Regulatory

New number of shares and votes in Vivesto

Vivesto AB (”Vivesto” or the ”Company”) has, as previously announced, completed a reverse share split, entailing that one hundred (100) shares were consolidated into one (1) share (reverse share split 1:100).

Through the reverse share split, the number of shares and votes in the Company has decreased by 1,096,065,541.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 11,071,369.

For More Information:

Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.

Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

This information is information that Vivesto AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-05-29 08:00 CEST.

Attachments

New number of shares and votes in Vivesto

Documents